Shots:
The companies collaborated to develop & deliver new medical device software i.e., ECG AI algorithms for earlier detection of heart disease
The AI will screen for atherosclerotic CV disease which can cause a heart attack or stroke. An evidence-based, digital point-of-care system will be created in order to improve medical therapies & lower the risk of hospitalizations and CV death
Each algorithm for these software solutions is currently in development as a candidate for marketing authorization through an FDA De Novo request. In a recent study presented by Mayo Clinic, single-lead ECGs from smartwatches were used to diagnose LV dysfunction using a modified version of Anumana’s 12-lead ECG algorithm
Ref: Bussinesswire | Image: Anumana
